ATHA
Athira Pharma Inc
$
0.458
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.470
Open
0.4569
VWAP
0.46
Vol
127.88K
Mkt Cap
17.88M
Low
0.440
Amount
58.50K
EV/EBITDA(TTM)
--
Total Shares
38.33M
EV
-18.79M
EV/OCF(TTM)
--
P/S(TTM)
--
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Show More
Valuation Metrics
The current forward P/E ratio for Athira Pharma Inc (ATHA.O) is -0.76, compared to its 5-year average forward P/E of -3.29. For a more detailed relative valuation and DCF analysis to assess Athira Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.29
Current PE
-0.76
Overvalued PE
1.01
Undervalued PE
-7.60
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.62
Undervalued EV/EBITDA
-5.96
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
50.27
Current PS
0.00
Overvalued PS
667.16
Undervalued PS
-566.62
Financials
Annual
Quarterly
FY2025Q1
YoY :
-65.56%
-9.54M
Operating Profit
FY2025Q1
YoY :
-65.28%
-9.14M
Net Income after Tax
FY2025Q1
YoY :
-66.67%
-0.23
EPS - Diluted
FY2025Q1
YoY :
-43.18%
-14.67M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.4K
USD
5
3-6
Months
0.0
USD
0
6-9
Months
31.4K
USD
5
0-12
Months
7.9K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.4K
USD
5
3-6
Months
0.0
USD
0
6-9
Months
31.4K
USD
5
0-12
Months
7.9K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATHA News & Events
Events Timeline
2025-05-13 (ET)
2025-05-13
11:07:49
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105
2025-02-27 (ET)
2025-02-27
16:26:45
Athira Pharma announces exploration of strategic alternatives
2025-02-27
16:25:27
Athira Pharma reports FY24 EPS ($2.52) vs. ($3.09) last year
Sign Up For More Events
Sign Up For More Events
News
9.0
05-13NewsfilterAthira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
4.0
02-28Business InsiderAthira Pharma (ATHA) Gets a Hold from JMP Securities
9.0
01-30SeekingAlphaAlterity surges after mid-stage trial data for lead asset
Sign Up For More News
People Also Watch
COCP
Cocrystal Pharma Inc
1.600
USD
-1.23%
BSGM
BioSig Technologies Inc
4.790
USD
-4.77%
SMSI
Smith Micro Software Inc
0.790
USD
+5.05%
ABTS
Abits Group Inc
4.620
USD
0.00%
GYRO
Gyrodyne LLC
8.650
USD
0.00%
CCTG
CCSC Technology International Holdings Ltd
1.081
USD
-3.14%
MIRA
Mira Pharmaceuticals Inc
1.730
USD
-0.57%
SDOT
Sadot Group Inc
1.080
USD
-1.82%
ATER
Aterian Inc
1.360
USD
0.00%
COSM
Cosmos Health Inc
0.697
USD
+18.14%
FAQ
What is Athira Pharma Inc (ATHA) stock price today?
The current price of ATHA is 0.458 USD — it has decreased -1.08 % in the last trading day.
What is Athira Pharma Inc (ATHA)'s business?
What is the price predicton of ATHA Stock?
What is Athira Pharma Inc (ATHA)'s revenue for the last quarter?
What is Athira Pharma Inc (ATHA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Athira Pharma Inc (ATHA)'s fundamentals?
How many employees does Athira Pharma Inc (ATHA). have?